The UK Health Research Analysis 2014 is a UK wide analysis of how 64 charity and public funders, which includes Ataxia UK, invested in 17,000 projects. It shows the similarities between charitable and government funders, and underlines how funders are thinking strategically about where their money can be put to best use to encourage research that will benefit patients. For example it showed that, much like our own research strategy, funders are investing in research for advancing diagnosis and translating discoveries into new treatments.
The gene therapy company AAVlife now holds a US patent for a new therapy they are developing which carries a frataxin expressing gene into cells. This is carried out using an adeno-associated virus (AAV), a harmless virus which is used to transport the gene.